Hepatitis C Information Central

The latest research & treatment news about Hepatitis C infection, diagnosis, symptoms and treatments here at Hepatitis-Central.com.

Hep C information
Free Newsletter
Hepatitis C Newsletter
We value your privacy. We will not rent your email to anyone.
HEPATITIS NEWS
The top stories compiled from over 5,500 sources, updated every 15 minutes

Extended Drug Therapy for Hepatitis Is Challenged
Patients who do not initially respond to standard drug therapy for treatment of hepatitis C are unlikely to respond to long-term maintenance therapy as well, according to a new study. Yet many patients who do not at first respond to drugs are placed on

Gilead Sciences, Inc. (GILD) Release: Data Demonstrating Significant Efficacy of Viread(R) in Treating Chronic Hepatitis B Published in New England Journal of Medicine
FOSTER CITY, Calif.--(BUSINESS WIRE)-- (Nasdaq: GILD) today announced the publication of detailed 48-week data from two Phase III pivotal clinical trials evaluating the safety and efficacy of its once-daily Viread (tenofovir disoproxil fumarate) for the

Interferon as long-term treatment for hepatitis C not effective
Results of the 3-year study, called the HALT-C (Hepatitis C Antiviral Long-Term Treatment Against Cirrhosis) Trial, appear in today's issue of . The researchers found no difference in the rate of progression of liver disease among patients who received

UPDATES AND COMMENTARY RSS Feed

Hep C Study Reveals Taribavirin a Good Alternative to Ribavirin
At the end of a 48-week, Phase IIb study, taribavirin shows similar effectiveness as ribavirin in reducing Hepatitis C viral load. However, participants taking taribavirin had a significantly lower rate of anemia....

Schering-Plough Developing Potent Protease Inhibitor for Hepatitis C
An ongoing Phase IIa study on Schering-Plough's next generation Hepatitis C protease inhibitor is encouraging. According to the company, SCH 900518 is 10 times more potent than other medications in this class and is active against highly resistant Hepatitis C...

New Drug Finds Viral Hiding Spots
A new, experimental drug helps the immune system locate a virus by flagging cells that have turned inside out. Hepatitis C is among the viruses that could benefit from Bavituximab's unique strategy of exposing a virus in hiding....

Am J Trop Med Hyg 1998 Mar;58(3):330-334

Role of Hepatitis E virus in sporadic cases of acute and fulminant hepatitis in an endemic area (Chad).

Coursaget P, Buisson Y, N'Gawara MN, Van Cuyck-Gandre H, Roue R

Institut de Virologie de Tours and Laboratoire d'Immunologie des Maladies Infectieuses, Faculte de Pharmacie, France.

Forty-one patients with acute or fulminant hepatitis and 86 control patients were entered into a study of sporadic, acute, and fulminant hepatitis in the N'Djamena area of Chad in 1993. Acute Hepatitis B was diagnosed in nine (22%) patients and acute Hepatitis E in 27 (66%) patients. No acute Hepatitis A was observed and 10% of the patients had serologic markers of Hepatitis C virus (HCV) infection. Dual acute Hepatitis B and E were observed in four patients (10%) and acute HEV infection was associated with chronic Hepatitis B surface antigen carriage in 16 (39%). Epidemiologic findings concerning HBV from Chad suggest that these patients had undiagnosed chronic liver disease due to HBV, with acute deterioration caused by superimposed HEV replication. Moreover, it is obvious that in developing countries only the most severe cases of hepatitis are seen in hospital settings and a large proportion of them are related to superinfection with HBV and HEV. Antibody to HEV was observed in 22% of the control patients. This observation and the fact that epidemic and sporadic cases of HEV are observed in Chad indicates that HEV is highly endemic in this country.

PMID: 9546413, UI: 98206489

  Hep C information

Information at this website is for educational purposes only; statements about products and health conditions
have not been evaluated by the U.S. Food & Drug Administration.

©1994-2008 Hepatitis-Central.com
Updated 05 Dec 2008